First two-drug regimen approved for HIV-1 treatment

(HealthDay)—The U.S. Food and Drug Administration has announced the approval of Dovato (dolutegravir and lamivudine), the first approved two-drug, fixed-dose, complete regimen for adults with HIV-1 who have not been previously ...


Long-acting regimen noninferior to daily ART for HIV-1

(HealthDay)—Monthly long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) are noninferior to daily regimens for patients with HIV-1, according to two studies presented at the Conference on Retroviruses and Opportunistic ...


Scientists report setbacks in quest for AIDS cure

Scientists reported setbacks Tuesday in the quest for an AIDS cure, and highlighted concerns about inconclusive evidence linking a promising new HIV drug to birth defects.


Dolutegravir in HIV-1 infection: Added benefit in adult patients

Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. In an early benefit ...

page 1 from 1